Yi Zhan Miao

2011 8,, 、 、 、.2012 2015,.2014 2021,. 、 、.,, 、,, 、 、 、,. 、 、 、 8; 、“ ”、“ ”. /meta 、,,. 、 (IUA) 、 、 、 、 、 、 、 、《 》 、《 》 、《BMJ Quality & Safety 》 、《American Journal of Health-System Pharmacy 》.《Frontier in pharmacology》、《Drug Safety》、《Journal of Chinese Pharmaceutical Sciences》、《 》. 、 、 、 、 (2 )、 (2 )、 、 、University of New York Completion with Honors., “ 27 ” 、. 80, 24,2 SCI /.: 1. Yi ZM, Zhong XL, Wang ML, Zhang Y, Zhai SD*. Efficacy, safety and economics of intravenous levetiracetam for status epilepticus: a systematic review and meta-analysis. Front Pharmacol. 2020,11:751. 2. Yi ZM, Men P, Qu S, Xiong T, Li C, Yu X, Zhai SD*. Comparative Cost-Effectiveness of Amisulpride and Olanzapine in the Treatment of Schizophrenia in China. Expert Rev Pharmacoecon Outcomes Res. 2020; 20:313-320. 3. Yi ZM, Wen C, Cai T, Xu L, Zhong XL, Zhan SY, Zhai SD*. Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles. Neuropsychiatr Dis Treat. 2019,15:1-19. 4. Yi ZM, Chen SD, Tang QY, Tang HL, Zhai SD*. Efficacy and safety of sertraline for the treatment of premature ejaculation: systematic review and meta-analysis. Medicine (Baltimore). 2019,98:e15989. 5. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD*. Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag. 2018,14:709-719. 6. Men P, Yi ZM, Li C, Qu S, Xiong T, Yu X, Zhai S*. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC Psychiatry. 2018,18:286. 7. Yi ZM, Qiu TT, Zhang Y, Liu ZY, Zhai SD*. Comparison of prophylactic effect of UGIB and effects on platelet function between PPIs and H 2 RAs combined with DAPT: systematic review and meta-analysis. Ther Clin Risk Manag. 2017,13: 367-377. 8. Yang HX, Chen K, Liang SY, Zhai SD, Yi ZM *. Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole. J Chin Pharm Sci. 2017,26: 202-211. 9. Yi ZM, Tang SD, Liu F*, Zhai SD, Jiao LG. Evaluation on rhabdomyolysis associated with telbivudine. J Chin Pharm Sci. 2016,25: 66-72. 10. Yi ZM, Sun SS, Li XX, Lu M, Zhai SD*. An evaluation of clinical pharmacist service on a neurology care unit.Int J Clin Pharm. 2016,38: 30-33. 11. Yi ZM, Zhi XJ, Yang L, Sun SS, Zhang Z, Sun ZM, Zhai SD*. Identify practice gaps of medication education through surveys to patients and physicians. Patient Prefer Adherence. 2015,9: 1423-1430. 12. Yi ZM,Zhao RS*,Zhai SD,Yang L,Hu YF,Yang YH,Zhang X,Tracy TS. Comparison of U.S. and Chinese pharmacy education programs. Am J Health Syst Pharm. 2014,71: 425-429. 13. Yi ZM, Zhao RS, Zhai SD*, Wang GL. Drug treatment for lower urinary tract symptoms in women with voiding dysfunction.Cochrane Database Syst Rev. 2014, Issue 8. Art. No.: CD011264. DOI: 10.1002/14651858.CD011264. 14. Yi ZM, Zhai SD, Huang S, Wang TS, Liu F*. Off-label Prescriptions for Adult Neurological Patients: A pilot survey in China. Int J Clin Pharm. 2012,34:81-87. 15. Yi ZM, Liu F, Zhai SD*, Belsh J, Zhan S Y, Schiffman P. Pharmacological interventions for improving respiratory function in amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2012, Issue 8. Art. No.:CD010030. DOI:10.1002/14651858. CD010030. 16. Yi ZM,Liu F*,Zhai SD. Zhai. Fluoxetine for the prophylaxis of post-stroke depression in patients with stroke: a meta-analysis. Int J Clin Pract. 2010,64:1310-1317. 17. Yi ZM,Liu F*,Zhai SD. Efficacy and safety of fluoxetine for the treatment of post-stroke depression: a meta-analysis. J Chin Pharm Sci. 2010,19:59-66. 80, 28 (2 / ). / 《 》 4, 1.